Abstract
Objective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: Wedesigned a cross-sectional study of 233 BC patients treated with AET andused the Functional Assessment of Cancer Therapy - Breast questionnaire. Results: No significant difference was observed between endocrine agents. Duration of AET did not affect QoL. In the entire cohort, multivariate analysis determined age (p=0.034) and switching treatment from tamoxifen to aromatase inhibitors (p=0.049) as significant positive coefficients of QoL, while comorbidity (p=0.072) tended to be associated with lower scores. Education level (p=0.001) and chemotherapy (p=0.04) were significant predictors of QoL in the tamoxifen group, while comorbidity (p=0.04), surgery type (p=0.02), radiotherapy (p=0.006) and stage (p=0.009) had a significant impact on QoL in aromatase inhibitors group. Conclusion: Evaluating the well-being of BC patients by QoL questionnaires is of great importance to identify particular subgroups that may require supportive care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
